- Home
- SEVN vs AGEN Comparison
SEVN vs AGEN Comparison
Compare SEVN & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SEVN | AGEN |
|---|---|---|
| Founded | 1986 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 140.2M | 126.2M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | SEVN | AGEN |
|---|---|---|
| Price | $9.13 | $3.23 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 2 |
| Target Price | $12.13 | ★ $14.50 |
| AVG Volume (30 Days) | 113.2K | ★ 901.2K |
| Earning Date | 02-18-2026 | 03-10-2026 |
| Dividend Yield | ★ 12.27% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.04 | N/A |
| Revenue | $29,408,000.00 | ★ $106,829,000.00 |
| Revenue This Year | $0.59 | $23.68 |
| Revenue Next Year | $14.72 | $23.17 |
| P/E Ratio | $8.80 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.30 | $1.38 |
| 52 Week High | $13.97 | $7.34 |
Technical Indicators
Market Signals| Indicator | SEVN | AGEN |
|---|---|---|
| Relative Strength Index (RSI) | 54.16 | 40.39 |
| Support Level | $8.83 | $3.12 |
| Resistance Level | $9.30 | $3.55 |
| Average True Range (ATR) | 0.21 | 0.38 |
| MACD | 0.03 | -0.04 |
| Stochastic Oscillator | 79.55 | 6.57 |
Price Performance
Historical ComparisonAbout SEVN Seven Hills Realty Trust
Seven Hills Realty Trust is a real estate investment trust. The company is engaged in the business of originating and investing in floating rate first mortgage loans secured by the middle market and transitional commercial real estate. Its primary objective is to balance capital preservation with generating risk-adjusted returns.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).